Study ID: CTSU S1211
Title:

A Randomized Phase I/II Study of Optimal Induction Therapy of Bortezomib, Dexamethasone and Lenalidomide with or without Elotuzumab (NSC-764479) for Newly Diagnosed High Risk Multiple Myeloma (HRMM)

Location:
Bemidji Clinic, Bismarck Region, Fargo Region
Principal Investigator:
Preston Steen, MD,Preston Steen, MD,Preston Steen, MD
Disease:
Multiple Myeloma
Stage:
Phase I/II

Status:

Active - Open to Accrual

For more information, call or email Bismarck Clinical Research at (701) 323-5760, Fargo and Bemidji Clinical Research at (701) 234-5890, or Sioux Falls Clinical Research at (605) 328-1368.

Back to Clinical Trials list